Australian (ASX) Stock Market Forum

IMU - Imugene Limited

The start of the rise in share price and volume is coincided with a "market sensitive" announcement 2/11/23
There has been another 2 market sensitive announcements since then, 6th &10th November.
The market seems to have liked it all.
Often though, there is just the star dust theory, but not in this case.
Is that the reason why the price has jumped 7% on the 27/11/2023?

Has everyone got their bonuses at the same time, and all decided to put it into IMU? Have they all waited for this day in particular to buy a position?

I was more so asking what has happened today that has caused a rise...

When looking at a 7% rise with no immediate recent announcements. Do you just go back and assume that it is from the announcement from the start of the month?

BTW its a 10% rise now...
 
IMU: IMUGENE LIMITED

I'm just using this stock as an example to learn something...

What is causing this price to rise? Is it purely from Morning stars Recommendation increasing from "Fairly Valued" to "Undervalued"?

No announcements (that i can see). Very high Volume of trades.

Rookie Question...

View attachment 166280View attachment 166282View attachment 166281

Iggy picked it in the monthly comp. Immediate response.

Could have been the RIH dart team too.

Or, maybe the CF33 study?

Has come off a bit...
 
@MDWake Check out the recent corporate news releases for reasons why the price has spiked.
Align the dates of the news with the price bars.

imu1.PNG


Positive early signs in a drug trial will tempt both speculators and investors causing an excess demand over supply.
 
A couple of things:

1. The two threads on IMU have now been merged.
2. Some off topic posts have been removed.

Let's please get back to discussing IMU. Thanks everyone.
 
looking to open higher in further news. There's a steady flow


FDA Fast Track Designation for Bile Duct Cancer granted for CF33-hNIS (VAXINIA) MAST Clinical Program
• FDA’s Fast Track Designation for CF33-hNIS (VAXINIA) offers closer cooperation with the FDA to expedite the MAST clinical program and subsequent potential approval process
• Fast Track provides eligibility for Accelerated Approval and Priority Review
• Imugene will utilise the Fast Track designation to work with the FDA on
advancing this important drug program towards patients on an accelerated timeline
 
IMU hit a low share price a couple of months ago. This was partly due to the market not liking companies with no revenue and partly by quite a few shareholders not understanding why multiple fundraisings have occurred and not understanding the amazing product that IMU has purchased with the last fundraise.

The ducks are all lined up now and some amazing trial results are expected over this next year. Results from some recent trials and these forthcoming trials will indicate IMU as a serious contended to kill a range of cancers, including solid cancers.
 
A couple of things:

1. The two threads on IMU have now been merged.
2. Some off topic posts have been removed.

Let's please get back to discussing IMU. Thanks everyone.
Should one of these threads be removed from the selection list @Joe Blow since they have been merged ?

Screenshot 2024-01-01 195245.jpg
 
IMU is one of my selections in the 2024 CY Comp. All my selections are made from a scan and flicking through charts.

@access in the post above makes some good points about IMU which gives me more hope to go along with what I'm seeing when looking at the chart.

Has the downtrend finished yet, I hope so but I might be getting in a little early on this.
The MAs are heading in the right direction at the moment and price is above them at the moment so that's good.

Screenshot 2024-01-01 220518.jpg
 
IMU is a stock I have held for some months with pride and sold with some profit.
I do believe this has an excellent future primarily driven by some exciting news published on ASX, the topic of research, competitveness and advanced stage of progress.
The following extract is to be understood as days and months to go in 2024.
On 11 Jan the presentation would let the world know many more and wait and see

https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02750496-3A632641 - THIS IS A GREAT NEWS. Phase 2
https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02750417-3A632617 - this has the element of human benefits in terms of oncology side and $$$ for investor perspective.
market cap is only $752 M and massive cash $104M to carry forward probably Phase 3 for some of its products, for such a sleeping giant
the one year road map of progression is great. There could be some serious ups or downs in Q4 2024.

1704122257023.png

1704121743298.png


 
2024 Comp January Update:

Only very early in the year and IMU price hasn't moved much and no sellers are dumping stock at the moment so that's a good sign.

I did notice a ASX Announcement on the 10/1/2024 titled Imugene Presentation to JPMorgan Healthcare Conference.
Hopefully this might bring on some large volume on buying in the near future, once digested.

 
2024 Comp January Update:

Only very early in the year and IMU price hasn't moved much and no sellers are dumping stock at the moment so that's a good sign.

I did notice a ASX Announcement on the 10/1/2024 titled Imugene Presentation to JPMorgan Healthcare Conference.
Hopefully this might bring on some large volume on buying in the near future, once digested.

For the benefit of those not read the presentation

 
Announcement from IMU - 15 February 2024

Phase 1 onCARlytics Trial Doses First Intravenous Patient​

Phase 1 onCARlytics trial doses first patient in intravenous monotherapy arm
Link below:
 
IMU, my 2024 tip. @debtfree - fulfilling the condition of one minimum posting per month :)
I am very positive on IMU future and surely by the end of Nov 24.
Not just wish but based on recommendations, company report and also seeing what stock specialists chart predict its performance as a strong buy :)




https://cdn-api.markitdigital.com/apiman-gateway/ASX/asx-research/1.0/file/2924-02768426-3A635633 DIRECTOR TRANSACTION



1709121731164.png


1709121804824.png
 

Attachments

  • 1709121663499.png
    1709121663499.png
    29.1 KB · Views: 2
IMU currently have 5 possible cancer cures in development trials and all are progressing as well as expected.

One of these trials is for Vaxinia. FDA are so impressed with the trial so far that in Nov '23 they provided Fast Track approval for the trial.

The success rates for Fast Track applications submitted to the FDA's Center for Drug Evaluation and Research (CDER) range between 70% and 80%.

So IMU are in regular communication with the FDA and, as IMU are treating a type of cancer that is not treatable at present, could possibly have trials finish earlier than normal if FDA are satified with results. IMU can then use this product treatment to then cross-over to treat other types of cancer with FDA consent.

A big year coming up.
 
Top